TG Therapeutics Inc (TGTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.18 is considered Undervalued compared with the five-year average of 23.12. The fair price of TG Therapeutics Inc (TGTX) is between 56.85 to 73.21 according to relative valuation method. Compared to the current price of 29.40 USD , TG Therapeutics Inc By Undervalued By 48.28%.

Relative Value

Fair Zone

56.85-73.21

Current Price：29.40

48.28%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is TG Therapeutics Inc (TGTX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

TG Therapeutics Inc (TGTX) has a current Price-to-Book (P/B) ratio of 6.88. Compared to its 3-year average P/B ratio of 30.00, the current P/B ratio is approximately -77.07% higher. Relative to its 5-year average P/B ratio of 22.07, the current P/B ratio is about -68.82% higher. TG Therapeutics Inc (TGTX) has a Forward Free Cash Flow (FCF) yield of approximately -1.64%. Compared to its 3-year average FCF yield of -1.98%, the current FCF yield is approximately -17.03% lower. Relative to its 5-year average FCF yield of -8.51%, the current FCF yield is about -80.73% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TGTX competitors is 24.15, providing a benchmark for relative valuation. TG Therapeutics Inc Corp (TGTX.O) exhibits a P/S ratio of 5.18, which is -78.55% above the industry average. Given its robust revenue growth of 78.00%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TGTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TGTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TGTX currently overvalued or undervalued?

What is TG Therapeutics Inc (TGTX) fair value?

TGTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of TG Therapeutics Inc (TGTX) is between 56.85 to 73.21 according to relative valuation method.

How does TGTX's valuation metrics compare to the industry average?

The average P/S ratio for TGTX's competitors is 24.15, providing a benchmark for relative valuation. TG Therapeutics Inc Corp (TGTX) exhibits a P/S ratio of 5.18, which is -78.55% above the industry average. Given its robust revenue growth of 78.00%, this premium appears sustainable.

What is the current P/B ratio for TG Therapeutics Inc (TGTX) as of Mar 02 2026?

As of Mar 02 2026, TG Therapeutics Inc (TGTX) has a P/B ratio of 6.88. This indicates that the market values TGTX at 6.88 times its book value.

What is the current FCF Yield for TG Therapeutics Inc (TGTX) as of Mar 02 2026?

As of Mar 02 2026, TG Therapeutics Inc (TGTX) has a FCF Yield of -1.64%. This means that for every dollar of TG Therapeutics Inc's market capitalization, the company generates -1.64 cents in free cash flow.

What is the current Forward P/E ratio for TG Therapeutics Inc (TGTX) as of Mar 02 2026?

As of Mar 02 2026, TG Therapeutics Inc (TGTX) has a Forward P/E ratio of 19.93. This means the market is willing to pay $19.93 for every dollar of TG Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for TG Therapeutics Inc (TGTX) as of Mar 02 2026?

As of Mar 02 2026, TG Therapeutics Inc (TGTX) has a Forward P/S ratio of 5.18. This means the market is valuing TGTX at $5.18 for every dollar of expected revenue over the next 12 months.

TGTX Valuation